Skip to main content
CND In the News

Phoenix Business Journal Highlights CND Life Sciences’ Plans to Expand, Hire More Staff

By November 4, 2020December 16th, 2020No Comments

Phoenix Business Journal Highlights CND Life Sciences’ Plans to Expand, Hire More Staff

Hiring slowed in the healthcare sector across the Valley during the coronavirus pandemic, but that trend is starting to reverse course, fueled in part by growing businesses such as CND Life Sciences.  

CND was recently awarded a $2.4 million grant from National Institutes of Health to further develop its Syn-One Test™, a simple skin test that helps physicians diagnose conditions like Parkinson’s disease and dementia with Lewy bodies.  

Next year, CND plans to move its Phoenix-based operation to a 10,000 square-foot facility in Scottsdale, and it expects to grow from 10 employees to more than 100 employees by 2025. 

READ THE ARTICLE
CND Life Sciences

CND Life Sciences is the creator of the Syn-One Test™, the world’s first commercially available test to visualize abnormal, phosphorylated alpha-synuclein in cutaneous nerve fibers. The test is an objective, evidence-based diagnostic tool to aid in the diagnosis of Parkinson’s disease, dementia with Lewy bodies, multiple system atrophy, pure autonomic failure, or REM sleep behavior disorder.